An integrative multi-omics investigation combined with single-cell sequencing and animal models has prioritized heme-binding protein 1, known as HEBP1, as a candidate risk-associated factor and mechanistic mediator for ischemic stroke. Stroke continues to present a major global health challenge, ranking as the second-leading cause of death and the third-leading contributor to disability worldwide.
To systematically investigate stroke-associated genes and potential therapeutic targets, researchers applied an integrative analytical framework. The workflow brought together diverse biological layers, analyzing DNA methylation, gene expression levels, and protein abundance datasets to map molecular traits linked to ischemic stroke vulnerability.
The investigative team implemented summary-data-based Mendelian randomization with heterogeneity in dependent instruments, or HEIDI, testing. This specialized approach enabled the identification of molecular traits that share a causal genetic variant with ischemic stroke.
To complement the primary evaluation, investigators performed two-sample Mendelian randomization using the inverse-variance weighted method alongside colocalization analysis.
Laboratory validation supported the computational predictions through animal experiments involving middle cerebral artery occlusion rat models.
Single-cell sequencing analyses further localized relatively high levels of HEBP1 expression to oligodendrocytes. The researchers observed that expression levels of HEBP1 varied along the inferred differentiation trajectory of these neural cells.
Subsequent immune-metabolic analyses highlighted potential roles for HEBP1 in pathways related to rejection, complement activation, and cholesterol homeostasis. Separately, a search of the Comparative Toxicogenomics Database identified 17 chemicals with curated associations to the HEBP1 protein.
Exploratory molecular docking simulations yielded a predicted binding score of minus 5.55 kilocalories per mole for phenobarbital. Because this modest in silico score and the database annotations do not establish direct biological binding or functional inhibition, the authors classified the chemical findings as hypothesis-generating.
The study concluded that while convergent genomic, cellular, and animal evidence prioritizes HEBP1 as a candidate mediator, therapeutic application remains premature. Cell-specific perturbations, brain-relevant molecular validations, and direct target-engagement studies are necessary to establish causal direction, evaluate safety, and assess therapeutic tractability.
Subject of Research: Prioritization of HEBP1 as a mechanistic target for ischemic stroke
Article Title: Multi-omics Mendelian randomization integrated with single-cell sequencing prioritizes HEBP1 as a candidate mechanistic target for ischemic stroke
Article References: Wang, X., Zhang, X., Zhang, Q., Qiu, Y., He, J., & Liu, R. (2026). Multi-omics Mendelian randomization integrated with single-cell sequencing prioritizes HEBP1 as a candidate mechanistic target for ischemic stroke. BMC Medical Genomics. https://doi.org/10.1186/s12920-026-02504-5
Image Credits: AI Generated
DOI: 10.1186/s12920-026-02504-5
Keywords: HEBP1, ischemic stroke, multi-omics, Mendelian randomization, single-cell sequencing, SMR, HEIDI test, colocalization analysis, MCAO rat model, Western blot, qPCR, oligodendrocytes, differentiation trajectory, complement activation, cholesterol homeostasis, phenobarbital, molecular docking
News Source: Cassandra Pierce. (November 19, 2026). Study Prioritizes HEBP1 as Candidate Mechanistic Target for Ischemic Stroke. Scienmag.



